Services
Platform
Technology & Data
Breast
Cervical
Esophageal
HER 2 Positive
Lung
Lymphoma
Melanoma
Myelofibrosis
Pancreatic
Pediatric
Prostate
A phase III randomized, double-blind, placebo-controlled study in participants with Myelofibrosis
We Provide Advanced Technology-Enabled Oncology Clinical Trial Services
We believe every cancer patient deserves the best chance to receive world-class healthcare options.
Contact Us What is Our Virtual Command Center?I am interested in
Clinical Trial Matching
All cancer patients deserve equal access to the latest in cancer care therapies and treatments. Refer a patient, friend, family member or loved one to get in touch with Massive Bio.
Refer a Patient
Pre-Screening
Massive Bio can improve your efficiency and patient satisfaction scores by pre-screening all cancer patients at your practice, at no cost to you. Patients are pre-screened with AI based technology for trials and advanced care options with sub-specialist and case management support.
Pre-screen Patients
Be Part of Our Oncologist Network
Join our growing network of key opinion leaders and oncologists. Your knowledge, research, and expertise in cancer treatment can make a difference.
Join Our Physician NetworkOther services we provide
Just In Time Activation
Multi-disciplinary background of experts like surgeons, radiation oncologists, pathologists, and medical oncologists gather to discuss treatment options for individual cancer patients.
EMR Activation
Instant access to patient EMR lets trial sites receive lab results, radiology reports, and even X-ray images electronically while ensuring tests are not duplicated. Machine learning technology for scaled pre-screening; prescreening in the matter of seconds instead of hours. Submit patient records digitally to expedite the pre-screening for the Synergy-AI clinical trial matching process.
Browse Recruiting Trials
Myelofibrosis
+18
Male & Female
Follicular Lymphoma/Marginal Zone Lymphoma
A phase III randomized, double-blind, placebo-controlled, multicenter study in patients with relapsed/refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Prostate Cancer
A phase III, randomized study for patients with Stage IV Adenocarcinoma of the Pancreas with no prior treatment for metastatic disease
Stage IV Pancreatic Cancer
A phase III, randomized study for patients with stage IV adenocarcinoma of the pancreas with no prior treatment for metastatic disease
HER2 Positive Solid Tumors, GE junction, Gastric Cancer
A Phase I/II, open-label, multicenter study in patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
Alteration/Biomarker-Positive Solid Tumors
A Phase II study in patients with Alteration/Biomarker-Positive Advanced or Metastatic Solid Tumors
Breast Cancer FGFR
A phase II, non-randomized clinical trial for patients with Metastatic Breast Cancers Harboring FGFR Amplifications
Cervical Cancer
A phase II randomized study in women with Recurrent/Persistent/Metastatic Cervical Cancer who have progressed following first-line therapy
Follicular Lymphoma/Marginal Zone Lymphoma
A phase III randomized, double-blind, placebo-controlled study in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Mantle Cell Lymphoma
A phase III randomized, double-blind study for the treatment of Newly Diagnosed Mantle Cell Lymphoma
Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
A phase 1b/2a basket study in adult patients with Relapsed/Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Non-Small Cell Lung Cancer MET
A first-in-human/phase I/II study for patients with Non-Small Cell Lung Cancer with MET Alteration
